Trials / Completed
CompletedNCT02139228
Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children
A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 426 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 5 Years – 6 Years
- Healthy volunteers
- Accepted
Summary
Evaluate the persistency of immune response against Haemophilus influenzae type b by assessing anti-PRP antibody levels in children vaccinated with either Hib-CRM197 or Hib-TT booster vaccine approximately 4 years before.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Hib-CRM197 | No vaccine administered in V37\_07E2 study |
| BIOLOGICAL | Hib-TT | No vaccine administered in V37\_07E2 study |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2014-12-01
- Completion
- 2015-01-01
- First posted
- 2014-05-15
- Last updated
- 2015-11-09
- Results posted
- 2015-11-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02139228. Inclusion in this directory is not an endorsement.